Monoclonal gammopathies of undetermined significance: a review Export

@article{citeulike:1399777, abstract = {Summary: Monoclonal gammopathy of undetermined significance (MGUS) denotes the presence of a monoclonal protein (M-protein) in patients without evidence of multiple myeloma (MM), macroglobulinemia, amyloidosis (AL), or a related plasma cell proliferative disorder. MGUS is found in approximately 3\% of persons older than 70 years and in about 1\% of those older than 50 years. In a series of 1384 patients from south-eastern Minnesota in whom MGUS was diagnosed at Mayo Clinic from 1960 through 1994, the risk of progression was 1\% per year. Patients were at risk of progression even after 25 years or more of a stable monoclonal gammopathy. The risk of development of MM was increased by 25-fold, the risk of macroglobulinemia was 46-fold, and the risk of primary AL was 8.4-fold when compared with a similar population (Surveillance, Epidemiology and End Results). The concentration of the serum M-protein was the major independent predictor of progression. Patients with an immunoglobulin M (IgM) or an IgA monoclonal gammopathy had a higher risk of progression than those with an IgG monoclonal gammopathy. The presence of a urine M-protein or the reduction of one or more uninvolved Igs was not a risk factor for progression. MGUS may be associated with many different disorders, including lymphoproliferative diseases, leukemia, connective tissue disorders, dermatologic diseases, and neurologic disorders.}, author = {Kyle, Robert A. and Rajkumar}, citeulike-article-id = {1399777}, citeulike-linkout-0 = {http://www.blackwell-synergy.com/doi/abs/10.1034/j.1600-065X.2003.00056.x}, citeulike-linkout-1 = {http://dx.doi.org/10.1034/j.1600-065X.2003.00056.x}, doi = {10.1034/j.1600-065X.2003.00056.x}, journal = {Immunological Reviews}, keywords = {hematopathology, mm}, number = {1}, pages = {112--139}, posted-at = {2007-06-20 04:10:13}, priority = {2}, title = {Monoclonal gammopathies of undetermined significance: a review}, url = {http://dx.doi.org/10.1034/j.1600-065X.2003.00056.x}, volume = {194}, year = {2003} }

TY - JOUR ID - citeulike:1399777 L3 - citeulike-article-id:1399777 N2 - Summary: Monoclonal gammopathy of undetermined significance (MGUS) denotes the presence of a monoclonal protein (M-protein) in patients without evidence of multiple myeloma (MM), macroglobulinemia, amyloidosis (AL), or a related plasma cell proliferative disorder. MGUS is found in approximately 3% of persons older than 70 years and in about 1% of those older than 50 years. In a series of 1384 patients from south-eastern Minnesota in whom MGUS was diagnosed at Mayo Clinic from 1960 through 1994, the risk of progression was 1% per year. Patients were at risk of progression even after 25 years or more of a stable monoclonal gammopathy. The risk of development of MM was increased by 25-fold, the risk of macroglobulinemia was 46-fold, and the risk of primary AL was 8.4-fold when compared with a similar population (Surveillance, Epidemiology and End Results). The concentration of the serum M-protein was the major independent predictor of progression. Patients with an immunoglobulin M (IgM) or an IgA monoclonal gammopathy had a higher risk of progression than those with an IgG monoclonal gammopathy. The presence of a urine M-protein or the reduction of one or more uninvolved Igs was not a risk factor for progression. MGUS may be associated with many different disorders, including lymphoproliferative diseases, leukemia, connective tissue disorders, dermatologic diseases, and neurologic disorders. IS - 1 JF - Immunological Reviews EP - 139 TI - Monoclonal gammopathies of undetermined significance: a review VL - 194 SP - 112 KW - hematopathology KW - mm AU - Kyle, Robert AU - Rajkumar PY - 2003/// UR - http://dx.doi.org/10.1034/j.1600-065X.2003.00056.x ER -